Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

• Status: Terminated
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is 1) to determine whether Imiquimod or Steroid pretreatment modifies UVB laser light response resulting in increased cell death compared to UVB laser light alone; 2) to determine if pretreatment of psoriatic lesions with Imiquimod or Steroid prior to UVB laser light exposure selectively effects various T cell functions; 3) to determine clinical results from the Imiquimod/Steroid/UVB laser light and correlate those changes with immuno-histochemical changes in the skin; and 4) to determine if single high dose lesion limited UVB laser light intervention combined with Imiquimod or Steroid influences T cell changes

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Office of Research and Development
• Collaborator: University Hospitals Cleveland Medical Center
• Treatments: Clobetasol; Imiquimod

Criteria

Inclusion Criteria:

• The presence of plaque-type psoriasis in areas of the trunk, buttocks, or extremities that are amenable to biopsy and evaluable disease in at least 2 cm target treatment sites separated by 1 cm

• Age 18-80, both genders, all ethnicities

• No contraindications to phototherapy or biopsy procedures

• No topical steroid, tar, phototherapy, Vitamin D, or retinoid therapy to target lesions for at least 1 week prior to the study

• No systemic psoriasis therapy for at least four weeks prior to the study

• Able to give informed consent under IRB approval procedures

Exclusion Criteria:

• Photosensitivity disorders

• Active untreated diseases or medication usage which may interfere with UVB, wound healing, or immune function

• Hypersensitivity to local anesthetic

• Inability to provide informed consent

• Pregnancy and /or lactating